January 7, 2020 Synthetic Biologics Receives FDA Guidance at Type C Meeting for SYN-004 (ribaxamase) Phase 1b/2a Clinical Trial in Allogeneic HCT Recipients
November 27, 2019 Synthetic Biologics Reports on NYSE American Noncompliance Notice and Compliance Plan
November 4, 2019 Synthetic Biologics Reports Third Quarter 2019 Operational Highlights and Financial Results
October 28, 2019 Synthetic Biologics to Report 2019 Third Quarter Operational Highlights and Financial Results on November 4, 2019
September 26, 2019 Synthetic Biologics Strengthens U.S. Patent Coverage of SYN-010, Intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
August 8, 2019 Synthetic Biologics Reports Second Quarter 2019 Operational Highlights and Financial Results
August 1, 2019 Synthetic Biologics to Report 2019 Second Quarter Operational Highlights and Financial Results on August 8, 2019
May 8, 2019 Synthetic Biologics Reports First Quarter 2019 Operational Highlights and Financial Results
April 30, 2019 Synthetic Biologics to Report 2019 First Quarter Operational Highlights and Financial Results on May 8, 2019
